Loading...
Market
Monte Rosa's market position in protein degradation by end of 2025?
2
Resolution / Starting Odds
Top 3 • 25%
Top 5 • 25%
Top 10 • 25%
Outside Top 10 • 25%
Industry reports or market analysis publications
Story
Monte Rosa Therapeutics Announces $150M Global License Agreement with Novartis
Oct 28, 2024, 10:30 AM
Monte Rosa Therapeutics ($GLUE) has announced a global license agreement with Novartis ($NVS) to advance T and B Cell-modulating VAV1-directed molecular glue degraders. The deal includes $150 million upfront and potential payments up to $2.1 billion. This agreement aims to enhance Monte Rosa's capabilities in the field of targeted protein degradation, competing with companies like Kymera Therapeutics.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
New partnership with a major pharma • 25%
Expansion of existing partnerships • 25%
No new partnership • 25%
Acquisition by another company • 25%
Top 3 • 25%
4th to 6th • 25%
7th to 10th • 25%
Below 10th • 25%
No milestone payments • 25%
Up to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Outside Top 5 • 25%
Mounjaro > 50% • 25%
Mounjaro 30-50% • 25%
Mounjaro 10-30% • 25%
Mounjaro < 10% • 25%
Positive response • 25%
Neutral response • 25%
Negative response • 25%
Mixed response • 25%
Increase by less than 10% • 25%
Increase by 10% to 20% • 25%
Increase by 20% to 30% • 25%
Increase by more than 30% • 25%